• In the News

    Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing with Equity Conversion Option at $5.5 Billion Valuation

    Read more


    Intarcia Names Top Commercial Expert Michael Williams as COO; Will Chair Commercial Committee and Lead ITCA 650 Launch in U.S.

    Read more

  • Message from the CEO

    Partnership with Servier Fuels our Vision to be Disruptive & Transformational

    Our new ex-U.S. partnership with Servier is likely the largest of its kind in biotech history. Servier is a well-suited strategic match for us outside the United States and has a shared vision for disruptive innovation.

    Read more

  • Two of the FREEDOM Phase 3 clinical trials are now successfully completed: FREEDOM-1 and the FREEDOM-1 HBL studies both met all their clinical endpoints. There are two remaining studies in the overall program: FREEDOM-2 and the FREEDOM-CVO Safety Study.

    Learn more about the FREEDOM Trials ›


  • Chairman & CEO Kurt Graves Explains the Vision and Culture of Intarcia

    What immediately sets Intarcia apart from other companies is what’s most visible – our product candidate that is built on amazing technology and chemistry. But what most outsiders cannot see is even more amazing – our people and our culture. Our people have a will to win. They are not intimidated by the skeptics who doubt that a relatively small biotech can change the course of treatment in serious disease. They say, "Watch us!"

    Hear Kurt Graves speak on this topic ›